Researchers investigate the effect of COVID-19 and its vaccination on the incidence and persistence of type 2 diabetes.
Silo Pharma set to Acquire Exclusive Licensing for Promising Alzheimer’s Disease Therapeutic | Psychedelic Invest
SARASOTA, FL, April 10, 2024 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations